Heron Therapeutics files for US approval of Cinvanti

13 January 2017
2019_biotech_test_vial_discovery_big

US specialty biotech group Heron Therapeutics (Nasdaq: HRTX) has submitted a New Drug Application (NDA) for Cinvanti (HTX-019), the first polysorbate 80-free, intravenous formulation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV), to the US Food and Drug Administration.

Aprepitant belongs to a class of agents known as NK1 receptor antagonists, which are often used in combination with 5-HT3 receptor antagonists for the prevention of CINV.

News of the filing saw Heron’s shares gain 3.2% to $12.90 by close of trading on Thursday.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology